Anti-epileptic Drugs for Pediatrics Market Explore Future Growth 2018-2026 by Global Top Players – Mylan N.V., Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc., Sanofi S.A., UCB Pharma Limited, Sunovion Pharmaceuti

The Global Anti-epileptic Drugs for Pediatrics Market by drug type (1st generation, 2nd generation, and 3rd generation) and region (North America, Latin America, Europe, Asia-Pacific, the Middle East and Africa) was valued at US$ 671.9 million in 2016 and is projected to exhibit a CAGR of 7.9% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Growing incidence of epilepsy and associated co-morbidities are expected to be the major factors driving growth of the global anti-epileptic drugs for pediatrics market over the foreseeable future.

Ask Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/823

Manufacturers are focusing on upgrading the available treatment options as well as developing new solutions for chronic as well as refractory epilepsies. Improving the therapeutic efficacy and effectiveness while lowering the side effects and interactions for better effects in adjunctive therapies is the epicenter of research and development for new treatment options in terms of drugs. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders also, in 2016, Pfizer, Inc.’s Lyrica (pregabalin) cleared phase-3 clinical trials for prescription to pediatric patients. Furthermore, UCB Pharma Limited received the U.S. FDA-approval for Briviact, for the treatment of patients with partial onset seizures.

Browse 25 Market Data Tables and 35 Figures spread through 200 Pages and in-depth TOC on " Anti-Epileptic Drugs for Pediatrics Market by Drug Type (1st generation, 2nd generation, and 3rd generation), and Region (North America, Latin America, Europe, Asia-Pacific, the Middle East and Africa) - Global Forecast to 2025"

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/823

Manufacturers are focusing on research and development activities of pipeline products and study about the effectiveness of generic drugs to find a solution to the existing problems associated with the treatment of epilepsy in children. In 2017, second trial conducted in the FDA-sponsored EQUIGEN project confirmed that generic version of lamotrigine is bioequivalent to Lamictal, which is the brand-name form of the drug. Furthermore, Sunovion submitted a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA), to use Aptiom (eslicarbazepine acetate) as monotherapy or adjunctive therapy in the treatment of partial-onset seizures (POS) for children of the age 4 years and below. Pfizer, Inc. has molecules NCT02072824, NCT01463306, and NCT01747915 for epilepsy in their pipeline. In 2017, Epygenix Therapeutics, Inc. received the U.S. FDA approval for orphan drug designation to EPX-100 and EPX-200 that are indicated for the treatment of patients suffering from Dravet syndrome, which is a catastrophic form of epilepsy.

Talk to Analyst @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/823

Key Takeaways of the Anti-epileptic Drugs for Pediatrics Market:

The global anti-epileptic drugs for pediatrics market is expected to exhibit a CAGR of 9% over the forecast period (2016–2025), owing to the presence of high potential markets, especially in Asia Pacific, Latin America, the Middle East, and Africa

Robust developments in drug therapies, drugs showing potential in pipeline, and inclusion of generic versions of branded products in the market due to patent expiries are expected to drive the global anti-epileptic drugs for pediatrics market.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,
#3200
Seattle, WA 98154

This release was published on openPR.